Acne in the adult female patient: A practical approach

International Journal of Dermatology

Volumn 51, Issue 10, 2012, Pages 1162-1174

  Kamangar, Faranak ^a   Shinkai, Kanade ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; ANDROSTENEDIONE; ANTIANDROGEN; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CORTICOTROPIN; CYANOCOBALAMIN; CYPROTERONE ACETATE; DANAZOL; DERMATOLOGICAL AGENT; ESTROGEN; GESTAGEN; GLUCOCORTICOID; GROWTH HORMONE; INSULIN; ISONIAZID; ISOTRETINOIN; LITHIUM; MELANOCORTIN; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PRASTERONE; PRASTERONE SULFATE; PYRIDOXINE; RIBOFLAVIN; SEROTONIN UPTAKE INHIBITOR; SOMATOMEDIN C; SPIRONOLACTONE; TESTOSTERONE; UNINDEXED DRUG;

ACNE VULGARIS; ADULT; ALGORITHM; AMENORRHEA; ANAMNESIS; BLEEDING; BONE DISEASE; BREAST TENDERNESS; CHLOASMA; CLINICAL FEATURE; DERMATOLOGIST; DIASTOLIC BLOOD PRESSURE; DIFFERENTIAL DIAGNOSIS; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; ENDOCRINE FUNCTION TEST; FATIGUE; FEMALE; FEMINIZATION; FLUID RETENTION; HEADACHE; HORMONAL THERAPY; HUMAN; HYPERANDROGENISM; HYPOSPADIAS; LIBIDO DISORDER; LOW DRUG DOSE; MEDICAL ASSESSMENT; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; METABOLIC PARAMETERS; MOOD CHANGE; NAUSEA; NONHUMAN; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; POTASSIUM BLOOD LEVEL; PREGNANCY; REVIEW; SEBUM SECRETION; SIDE EFFECT; SKIN EXAMINATION; SKIN MANIFESTATION; SYSTOLIC BLOOD PRESSURE; TERATOGENICITY; VIRILIZATION; WEIGHT GAIN;

ACNE VULGARIS; ADOLESCENT; ADULT; ANDROGEN ANTAGONISTS; CONTRACEPTIVES, ORAL, HORMONAL; DERMATOLOGIC AGENTS; FEMALE; FLUTAMIDE; HUMANS; MALE; POLYCYSTIC OVARY SYNDROME; PREGNANCY; SPIRONOLACTONE; YOUNG ADULT;

EID: 84866560993     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2012.05519.x     Document Type: Review

References (65)

1. Kraning KK, Odland GF. Prevalence, morbidity, and cost of dermatologic diseases. J Invest Dermatol 1979; 73: 395-401.
2. James WD. Clinical practice. Acne. N Engl J Med 2005; 352: 1463-1472.
3. Lello J, Pearl A, Arroll B, et al. Prevalence of acne vulgaris in Auckland senior high school students. N Z Med J 1995; 108: 287-289.
4. Yentzer BA, Hick J, Reese EL, et al. Acne vulgaris in the United States: a descriptive epidemiology. Cutis 2010; 86: 94-99.
5. Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol 1999; 41: 577-580.
6. Poli F, Dreno B, Verschoore M. An epidemiological study of acne in female adults: results of a survey conducted in France. J Eur Acad Dermatol Venereol 2001; 15: 541-545.
7. Collier CN, Harper JC, Cafardi JA, et al. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol 2008; 58: 56-59.
8. Goulden V, McGeown CH, Cunliffe WJ. The familial risk of adult acne: a comparison between first-degree relatives of affected and unaffected individuals. Br J Dermatol 1999; 141: 297-300.
9. Goulden V, Clark SM, Cunliffe WJ. Post-adolescent acne: a review of clinical features. Br J Dermatol 1997; 136: 66-70.
10. Gupta MA, Gupta AK. The psychological comorbidity in acne. Clin Dermatol 2001; 19: 360-363.
11. Lasek RJ, Chren MM. Acne vulgaris and the quality of life of adult dermatology patients. Arch Dermatol 1998; 134: 454-458.
12. Kligman AM, Mills OH Jr. Acne cosmetica. Arch Dermatol 1972; 106: 843-850.
13. Harper JC. Evaluating hyperandrogenism: a challenge in acne management. J Drugs Dermatol 2008; 7: 527-530.
14. Lucky AW, Biro FM, Huster GA, et al. Acne vulgaris in premenarchal girls. An early sign of puberty associated with rising levels of dehydroepiandrosterone. Arch Dermatol 1994; 130: 308-314.
15. Lucky AW, Biro FM, Huster GA, et al. Acne vulgaris in early adolescent boys. Correlations with pubertal maturation and age. Arch Dermatol 1991; 127: 210-216.
16. Thiboutot D. Acne: hormonal concepts and therapy. Clin Dermatol 2004; 22: 419-428.
17. Imperato-McGinley J, Gautier T, Cai LQ, et al. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metab 1993; 76: 524-528.
18. Lolis MS, Bowe WP, Shalita AR. Acne and systemic disease. Med Clin North Am 2009; 93: 1161-1181.
19. Chen MJ, Chen CD, Yang JH, et al. High serum dehydroepiandrosterone sulfate is associated with phenotypic acne and a reduced risk of abdominal obesity in women with polycystic ovary syndrome. Human Reprod 2011; 26: 227-234.
20. George R, Clarke S, Thiboutot D. Hormonal therapy for acne. Semin Cutan Med Surg 2008; 27: 188-196.
21. Stoll S, Shalita AR, Webster GF, et al. The effect of the menstrual cycle on acne. J Am Acad Dermatol 2001; 45: 957-960.
22. Lucky AW. Quantitative documentation of a premenstrual flare of facial acne in adult women. Arch Dermatol 2004; 140: 423-424.
23. Capitanio B, Sinagra JL, Bordignon V, et al. Underestimated clinical features of postadolescent acne. J Am Acad Dermatol 2010; 63: 782-788.
24. Lucky AW, Biro FM, Simbartl LA, et al. Predictors of severity of acne vulgaris in young adolescent girls: results of a five-year longitudinal study. J Pediatr 1997; 130: 30-39.
25. Haider A, Shaw JC. Treatment of acne vulgaris. JAMA 2004; 292: 726-735.
26. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007; 370: 685-697.
27. Lucky AW. Hormonal correlates of acne and hirsutism. Am J Med 1995; 98: 89S-94S.
28. Stein LLM. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29: 181-191.
29. Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83: 3078-3082.
30. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999; 84: 4006-4011.
31. Davis SR, Knight S, White V, et al. Preliminary indication of a high prevalence of polycystic ovary syndrome in indigenous Australian women. Gynecol Endocrinol 2002; 16: 443-446.
32. Rodin DA, Bano G, Bland JM, et al. Polycystic ovaries and associated metabolic abnormalities in Indian subcontinent Asian women. Clin Endocrinol (Oxf) 1998; 49: 91-99.
33. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25.
34. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352: 1223-1236.
35. Lowenstein EJ. Diagnosis and management of the dermatologic manifestations of the polycystic ovary syndrome. Dermatol Ther 2006; 19: 210-223.
36. Lee AT, Zane LT. Dermatologic manifestations of polycystic ovary syndrome. Am J Clin Dermatol 2007; 8: 201-219.
37. Ozdemir S, Ozdemir M, Gorkemli H, et al. Specific dermatologic features of the polycystic ovary syndrome and its association with biochemical markers of the metabolic syndrome and hyperandrogenism. Acta Obstet Gynecol Scand 2010; 89: 199-204.
38. Archer JS, Chang RJ. Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004; 18: 737-754.
39. Guastella E, Longo RA, Carmina E. Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes. Fertil Steril 2010; 94: 2197-2201.
40. Vgontzas AN, Legro RS, Bixler EO, et al. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab 2001; 86: 517-520.
41. Harrison CL, Lombard CB, Moran LJ, Teede HJ. Exercise therapy in polycystic ovary syndrome: a systematic review. Hum Reprod Update 2011; 17: 171-183.
42. Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol 2009; 60(5 Suppl): S1-S50.
43. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49(1 Suppl.): S1-S37.
44. Rademaker M. Adverse effects of isotretinoin: a retrospective review of 1743 patients started on isotretinoin. Australas J Dermatol 2010; 51: 248-253.
45. Amichai B, Shemer A, Grunwald MH. Low-dose isotretinoin in the treatment of acne vulgaris. J Am Acad Dermatol 2006; 54: 644-646.
46. Katsambas AD, Dessinioti C. Hormonal therapy for acne: why not as first line therapy? facts and controversies. Clin Dermatol 2010; 28: 17-23.
47. Frangos JE, Alavian CN, Kimball AB. Acne and oral contraceptives: update on women's health screening guidelines. J Am Acad Dermatol 2008; 58: 781-786.
48. Steinkellner A, Chen W, Denison SE. Adherence to oral contraception in women on Category X medications. Am J Med 2010; 123: 929-934.
49. Vessey M, Painter R, Yeates D. Mortality in relation to oral contraceptive use and cigarette smoking. Lancet 2003; 362: 185-191.
50. Lidegaard O. Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol. J Obstet Gynaecol Can 2003; 25: 575-577.
51. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1996; 347: 1713-1727.
52. Schlesselman JJ. Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner's guide to meta-analysis. Hum Reprod 1997; 12: 1851-1863.
53. Hankinson SE, Colditz GA, Hunter DJ, et al. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol 1992; 80: 708-714.
54. Junkins-Hopkins JM. Hormone therapy for acne. J Am Acad Dermatol 2010; 62: 486-488.
55. London BM, Lookingbill DP. Frequency of pregnancy in acne patients taking oral antibiotics and oral contraceptives. Arch Dermatol 1994; 130: 392-393.
56. Helms SE, Bredle DL, Zajic J, et al. Oral contraceptive failure rates and oral antibiotics. J Am Acad Dermatol 1997; 36(5 Pt 1): 705-710.
57. Brown J, Farquhar C, Lee O, et al. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev 2009; CD000194.
58. Shaw JC. Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol 2000; 43: 498-502.
59. Krunic A, Ciurea A, Scheman A. Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone. J Am Acad Dermatol 2008; 58: 60-62.
60. Shaw JC, White LE. Long-term safety of spironolactone in acne: results of an 8-year followup study. J Cutan Med Surg 2002; 6: 541-545.
61. Tan J. Hormonal treatment of acne: review of current best evidence. J Cutan Med Surg 2004; 8(Suppl 4): 11-15.
62. van Vloten WA, van Haselen CW, van Zuuren EJ, et al. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002; 69: 2-15.
63. Williams C, Layton AM. Persistent acne in women: implications for the patient and for therapy. Am J Clin Dermatol 2006; 7: 281-290.
64. Murase J. Fulfilling great expectations: caring for new mothers and mothers-to be American Academy of Dermatology 69th Annual Meeting. New Orleans, LA, 2011.
65. Sannerstedt R, Lundborg P, Danielsson BR, et al. Drugs during pregnancy: an issue of risk classification and information to prescribers. Drug Saf 1996; 14: 69-77.